Orlistat: In the prevention and treatment of type 2 diabetes mellitus

Drugs

Volumn 61, Issue 14, 2001, Pages 2107-2119

  Keating, G M ^a   Jarvis, B ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; AMITRIPTYLINE; ANTIDIABETIC AGENT; ATENOLOL; ATORVASTATIN; BETA CAROTENE; CAPTOPRIL; CARBON 14; CERIVASTATIN; CYCLOSPORIN; DIGOXIN; FUROSEMIDE; GLIBENCLAMIDE; IMMUNOSUPPRESSIVE AGENT; INSULIN; LOSARTAN; METFORMIN; NIFEDIPINE; ORAL ANTIDIABETIC AGENT; ORAL CONTRACEPTIVE AGENT; PHENTERMINE; PHENYTOIN; PLACEBO; PRAVASTATIN; RETINOL; SIBUTRAMINE; SULFONYLUREA DERIVATIVE; TETRAHYDROLIPSTATIN; TRIACYLGLYCEROL LIPASE; UNINDEXED DRUG; WARFARIN;

BODY WEIGHT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIABETES MELLITUS; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; FECES INCONTINENCE; FLATULENCE; GASTROINTESTINAL TOXICITY; GLUCOSE BLOOD LEVEL; HUMAN; IMPAIRED GLUCOSE TOLERANCE; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; RANDOMIZED CONTROLLED TRIAL; REVIEW; TREATMENT OUTCOME;

EID: 0035215569     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200161140-00011     Document Type: Review

References (72)

1. Obesity, fat distibution, and weight gain as risk factors for clinical diabetes in men
2. Weight gain as a risk factor for clinical diabetes mellitus in women
3. The impact of pharmacotherapy on weight management in type 2 diabetes
4. Is continued weight gain inevitable in type 2 diabetes mellitus?
5. The prevention and treatment of obesity: Application to type 2 diabetes
6. The treatment of obesity in type 2 diabetes mellitus
7. Beneficial health effects of modest weight loss
8. Long-term effects of modest weight loss in type II diabetic patients
9. Mode of action of orlistat
10. Orlistat: A review of its use in the management of obesity
11. One-year treatment of obesity: A randomized, double-blind, placebo-controlled, multicentre study of orlistat, a gastrointestinal lipase inhibitor
12. Orlistat, a lipase inhibitor, for weight maintenance after conventional dieting: One 1-y study
13. The effect of orlistat on body weight and coronary heart disease risk profile in obese patients: The Swedish multimorbidity study
14. Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity
15. Orlistat in the long-term treatment of obesity in primary care settings
16. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients
17. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat
18. Orlistat associated with a hypocaloric diet in obese patients promotes and maintains weight loss during an 18-month period
19. Efficacy and safety of orlistat plus a reduced-calorie diet in obese non-diabetic patients: A 1-year Austrian multicentre study
20. Orlistat (RO 18-0647), a lipase inhibitor, in the treatment of human obesity: A multiple dose study
21. Efficacy and tolerability of orlistat in the treatment of obesity: A 6-month dose-ranging study
22. Role of lipase in the regulation of postprandial gastric acid secretion and emptying of fat in humans: A study with orlistat, a highly specific lipase inhibitor
23. Inhibition of pancreatic lipase in vitro by the covalent inhibitor tetrahydrolipstatin
24. Large spectral changes accompany the conformational transition of human pancreatic lipase induced by acylation with the inhibitor tetrahydrolipstatin
25. Orlistat fails to alter postprandial plasma lipid excursions or plasma lipases in normal-weight male volunteers
26. Retrospective population-based analysis of the dose-response (fecal fat excretion) relationship of orlistat in normal and obese volunteers
27. Orlistat (Xenical®) improves insulin sensitivity in obese intentionally weight maintaining subjects
28. Evaluation of the safety and efficacy of sibutramine, orlistat and metformin in the treatment of obesity
29. Effect of orlistat on cardiovascular risk factors and insulin sensitivity in young obese Chinese type 2 diabetic patients
30. A pilot study of the efficacy of orlistat in overweight adolescents
31. Effect of orlistat on postprandial metabolism in healthy subjects
32. Review of limited systemic absorption of orlistat, a lipase inhibitor, in healthy human volunteers
33. Metabolic profiles of minimally absorbed Orlistat in obese/overweight volunteers
34. Long-term systemic exposure of orlistat, a lipase inhibitor, and its metabolites in obese patients
35. The effect of orlistat, an inhibitor of dietary fat absorption, on the absorption of vitamins A and E in healthy volunteers
36. The effect of orlistat, an inhibitor of dietary fat absorption, on the pharmacokinetics of β-carotene in healthy volunteers
37. The influence of orlistat on the pharmacokinetics and pharmacodynamics of glyburide in healthy volunteers
38. The effect of orlistat on the pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers
39. Effect of orlistat, a novel antiobesity agent, on the pharmacokinetics and pharmacodynamics of pravastatin in patients with mild hypercholesterolaemia
40. Lack of pharmacokinetic drug-drug interaction between orlistat and cerivastatin
41. The influence of reduced dietary fat absorption induced by orlistat on the pharmacokinetics of digoxin in healthy volunteers
42. The effect of orlistat on the pharmacokinetics of phenytoin in healthy volunteers
43. Lack of effect of orlistat on the bioavailability of a single dose of nifedipine extended-release tablets (Procardia XL) in healthy volunteers
44. Effect of the lipase inhibitor orlistat on the pharmacokinetics of four different antihypertensive drugs in healthy volunteers
45. Lack of interaction between orlistat and oral contraceptives
46. The interaction of the lipase inhibitor orlistat with ethanol in healthy volunteers
47. Co-administration of orlistat and cyclosporine in a heart transplant recipient
48. Effect of orlistat on blood cyclosporin concentration in an obese heart transplant recipient
49. Orlistat decreases the plasma level of cyclosporine and may be responsible for the development of acute rejection episodes
50. Effects of weight loss with orlistat on glucose tolerance and progression to type 2 diabetes in obese adults
51. Treatment with orlistat reduces cardiovascular risk in obese patients
52. A pharmacoeconoic analysis of weight-reduction therapy in a hypothetical cohort of obese Chinese patients with impaired glucose tolerance
53. Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomized double-blind study
54. Orlistat promotes glucemia control and other cardiovascular risk factors lowering in obese patients with type 2 diabetes: Randomised clinical trial
55. Effect of orlistat in overweight and obese type 2 diabetes patients treated with metformin
56. Effect of orlistat in overweight patients with type 2 diabetes receiving insulin therapy
57. Effect of treatment with orlistat in overweight or obese Thai patients with type 2 diabetes
58. Latin-American multicentric study with orlistat in overweight or obese patients with type diabetes
59. Improvement of metabolic control in obese type 2 diabetic patients treated with orlistat for 6 months
60. Orlistat promotes weight loss and improves glycaemic control in overweight patients with type 2 diabetes
61. Orlistat reduces body weight and cardiovascular disease risk factors in obese men and women with type 2 diabetes
62. Effect of weight loss with orlistat on cardiovascular disease risk prediction in type 2 diabetes
63. Early weight loss response to diet + orlistat predicts long-term improvement in glycemic control in type 2 diabetes
64. Impact of orlistat on fasting hyperglycemia in obese patients with type 2 diabetes mellitus
65. Effects of orlistat in obese metformin-treated patients with type 2 diabetes: Attainment of treatment goals
66. Effect of orlistat on weight loss and glycemic control in overweight Chinese patients with type 2 diabetes
67. The effects of orlistat on body composition in obese diabetic and non-diabetic Chinese adults
68. Orlistat reduces visceral fat independent of weight changes in obese diabetics type 2
69. Gastrointestinal effects of orlistat plus metformin in obese patients with type 2 diabetes mellitus